7,718.60

-29.11

-0.38%

53,414.25

-271.86

-0.51%

26,506.99

-77.11

-0.29%

2,975.65

+7.38

+0.25%

14.53

+0.21

+1.47%

4,476.60

-63.30

-1.39%

79,670.23

-1,550.96

-1.91%

Crude Oil Oct 26

91.48

+0.18

+0.20%

NasdaqGS - Delayed Quote USD

Stoke Therapeutics, Inc. (STOK)

29.81 -0.18 (-0.60%)

At close: September 4 at 4:00:00 PM EDT

29.81 0.00 (0.00%)

After hours: September 4 at 7:30:03 PM EDT

Trade STOK on Coinbase

Loading Chart for STOK

Chart Range Bar

Interval:

In partnership with ChartIQ

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts

Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts

Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript

Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript

What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing?

What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing?

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

ALEC

IDYA

KYMR

BDTX

DNLI

PTGX

ANAB

GOSS

COGT

SRRK

Mobilize your Website

View Site in Mobile | Classic

Share by: